comprehensive -WSS

comprehensive

author：fashion 2025-09-27 09:57:42 - browse：42293

U.S. Sen. Bernie Sanders sets his hands on two chairs as two people set up a board displaying a "price of drugs" chart behind him — politics coverage from STAT — Sen. Bernie Sanders has used his leadership of a Senate committee to pressure drugmakers to lower their prices. Kevin Dietsch/Getty Images

WASHINGTON — Bernie Sanders is figuring out just how far bullying drugmakers can take him.

For more than a year, Sanders has used his perch atop the Senate health committee to haul the CEOs of pharmaceutical companies that make insulin, vaccines, and more before the panel with progressively more ambitious demands related to their pricing. After a few victories he’s claimed — experts say some credit is deserved, but the full story is a bit more complicated — he’s now progressed to demanding that Novo Nordisk cut its price for its novel, wildly popular diabetes and weight-loss drugs.

Sanders (I-Vt.) is testing the limits of the powers of a Senate chairman with little hope of advancing his policy agenda legislatively. He’s threatened subpoenas, held a prominent nominee hostage, and initiated investigations to get his way. It’s a sharp departure from the modest, bipartisan ambitions that more disciplined, discreet leaders of the committee have taken in years past, and sets the bar for how much can be accomplished using the full extent of the bully pulpit.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily intelligence on Capitol Hill and the life sciences industry — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： The Supreme Court will review a ruling striking down a domestic violence federal gun ban
Next article： Hey, doctors: Don't be no

knowledge

WSS

JPM pitch from hospitals? Revenue streams outside of patient care

Language on climate change, ESG removed from company website of Montana GOP Senate candidate

Allen Institute goes after foundational questions, CEO Costa says

Gene therapy denied for Afghan refugee whose father aided U.S.

A preacher's new calling: Diversifying neuroscience research

Mayo Clinic partners with supercomputer AI firm Cerebras at JPM

focus

comprehensive

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily intelligence on Capitol Hill and the life sciences industry — by subscribing to STAT+.

focus

The high cost of giving birth even with insurance

Why Marc Tessier

New air purifier tech could be key to improving indoor air quality

It's time to take a new tack for treating Alzheimer's

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Stories you might have missed in 2023: health, science, medicine

Hepatitis C has a cure — but many Americans still lack access to it

Ascension's ugly legal battle over care for poor patients in Texas

Psychedelics group wrestles with new pharma identity

Male doctors called my cancer incurable. A female doctor showed it wasn't

focus

Reframing the conversation around gain

Merck to acquire Harpoon Therapeutics for $680 million

What is the Turing Test that determines if computers can think?

JPM pitch from hospitals? Revenue streams outside of patient care

What is the Turing Test that determines if computers can think?

Study: Misdiagnosis causes 800,000 deaths, serious disabilities a year in U.S.

knowledge

focus

entertainment

focus